Currently, in NSCLC, initial management begins with searching for targetable drivers such as EGFR, ALK, ROS-1, NTRK, RET, NRG or BRAF, MET; however, for patients without such mutations, treatment options are limited [2]. Here, EGFR is linked to non-small cell lung carcinoma.